Rivastigmine transdermal - Teikoku Pharma USA

Drug Profile

Rivastigmine transdermal - Teikoku Pharma USA

Latest Information Update: 07 Mar 2016

Price : $50

At a glance

  • Originator Teikoku Pharma USA
  • Class Antidementias; Phenylcarbamates; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 04 Mar 2016 Preclinical trials in Alzheimer's disease in USA (Transdermal) before March 2016
  • 08 Oct 2015 Teikoku Pharma USA has patent protection for rivastigmine transdermal in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top